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Background
Gut-selective blockade of lymphocyte trafficking by vedolizumab may constitute 
effective treatment for ulcerative colitis.
Methods
We conducted two integrated randomized, double-blind, placebo-controlled trials of 
vedolizumab in patients with active disease. In the trial of induction therapy, 374 pa-
tients (cohort 1) received vedolizumab (at a dose of 300 mg) or placebo intravenously 
at weeks 0 and 2, and 521 patients (cohort 2) received open-label vedolizumab at weeks 
0 and 2, with disease evaluation at week 6. In the trial of maintenance therapy, patients 
in either cohort who had a response to vedolizumab at week 6 were randomly assigned 
to continue receiving vedolizumab every 8 or 4 weeks or to switch to placebo for up to 
52 weeks. A response was defined as a reduction in the Mayo Clinic score (range, 0 to 
12, with higher scores indicating more active disease) of at least 3 points and a de-
crease of at least 30% from baseline, with an accompanying decrease in the rectal 
bleeding subscore of at least 1 point or an absolute rectal bleeding subscore of 0 or 1.
Results
Response rates at week 6 were 47.1% and 25.5% among patients in the vedolizumab 
group and placebo group, respectively (difference with adjustment for stratification 
factors, 21.7 percentage points; 95% confidence interval [CI], 11.6 to 31.7; P<0.001). At 
week 52, 41.8% of patients who continued to receive vedolizumab every 8 weeks and 
44.8% of patients who continued to receive vedolizumab every 4 weeks were in clinical 
remission (Mayo Clinic score ≤2 and no subscore >1), as compared with 15.9% of pa-
tients who switched to placebo (adjusted difference, 26.1 percentage points for vedoliz-
umab every 8 weeks vs. placebo [95% CI, 14.9 to 37.2; P<0.001] and 29.1 percentage 
points for vedolizumab every 4 weeks vs. placebo [95% CI, 17.9 to 40.4; P<0.001]). The 
frequency of adverse events was similar in the vedolizumab and placebo groups.
Conclusions
Vedolizumab was more effective than placebo as induction and maintenance 
 therapy for ulcerative colitis. (Funded by Millennium Pharmaceuticals; GEMINI 1 
ClinicalTrials.gov number, NCT00783718.)
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Ulcerative colitis is a chronic in-flammatory bowel disease characterized by symptoms of bloody diarrhea, abdom-
inal cramps, and fatigue.1 Current medical thera-
py has important limitations. Aminosalicylates2-4 
are only modestly effective; glucocorticoids can 
cause unacceptable adverse events and do not 
provide a benefit as maintenance therapy. Tumor 
necrosis factor (TNF) antagonists, although ef-
ficacious,5,6 predispose patients to serious infec-
tion.7 Thus, new treatment strategies are needed.
The migration of leukocytes into inflamed 
intestinal tissue is highly regulated by specific 
molecular mechanisms. The α4β7 integrin,
8 a cell-
surface glycoprotein variably expressed on circulat-
ing B and T lymphocytes, interacts with mucosal 
addressin-cell adhesion molecule 19 (MAdCAM-1) 
on intestinal vasculature.10,11 Vedolizumab (Millen-
nium Pharmaceuticals), a humanized monoclonal 
antibody that specifically recognizes the α4β7 
heterodimer, selectively blocks gut lymphocyte 
trafficking without interfering with trafficking 
to the central nervous system.12-15 A predecessor 
molecule (MLN02) showed proof of concept in a 
phase 2 trial.16 Natalizumab, a monoclonal anti-
body with efficacy in multiple sclerosis and in 
Crohn’s disease, inhibits both α4β1 and α4β7 in-
tegrins and has been associated with progressive 
multifocal leukoencephalopathy (PML), a serious 
brain infection. Natalizumab and vedolizumab 
differ in that natalizumab blocks lymphocyte 
trafficking to multiple organs, including the 
brain and gut.17,18 We evaluated the efficacy and 
safety of vedolizumab in patients with ulcerative 
colitis.
Me thods
Study Design
This phase 3, randomized, double-blind, placebo-
controlled study consisted of separate induction 
and maintenance trials and was conducted at 
211 medical centers (including 15 at which en-
rollment was discontinued) (see the Supplemen-
tary Appendix, available with the full text of this 
article at NEJM.org) in 34 countries from 2008 to 
2012. The protocol was approved by an investiga-
tional review board at each center. All patients 
gave written informed consent. The study was 
conducted and reported in accordance with the 
protocol, available at NEJM.org.
Patients
Eligible patients were 18 to 80 years of age and 
had active ulcerative colitis, defined as a Mayo 
Clinic score19,20 (range, 0 to 12, with higher scores 
indicating more active disease) of 6 to 12, with a 
sigmoidoscopy subscore of at least 2, and disease 
that extended 15 cm or more from the anal verge. 
An additional eligibility criterion was documen-
tation of unsuccessful previous treatment (i.e., lack 
of response or unacceptable adverse events) with 
one or more glucocorticoids, immunosuppressive 
medications (i.e., azathioprine and 6-mercap-
topurine), or TNF antagonists (Table S1 in the 
Supplementary Appendix). Participants could con-
tinue to take mesalamine, up to 30 mg of predni-
sone (or the equivalent) per day, or immunosup-
pressive agents at stable doses. Rectal therapy 
with mesalamine or glucocorticoids was discon-
tinued 2 weeks before screening. Patients were 
ineligible if they had received TNF antagonists 
within 60 days before enrollment or cyclospo-
rine, thalidomide, or investigational drugs with-
in 30 days before enrollment, or if they had been 
treated previously with vedolizumab, natalizumab, 
efalizumab, or rituximab. Other exclusion criteria 
were toxic megacolon, abdominal abscess, symp-
tomatic colonic stricture, stoma, a history of col-
ectomy, an increased risk of infectious complica-
tions (e.g. as a result of recent pyogenic infection, 
enteric pathogens detected on stool analysis, 
 active or latent tuberculosis, immunodeficiency, 
hepatitis B or C, or recent live vaccination), clini-
cally meaningful laboratory abnormalities, preg-
nancy or lactation, an unstable or uncontrolled 
medical disorder, an anticipated requirement for 
major surgery, colonic dysplasia or adenomas, and 
malignant neoplasms.
Screening and Baseline Studies
Assessments that were performed before random-
ization were physical and neurologic examina-
tions, blood tests, stool analysis for enteric patho-
gens and fecal calprotectin,21 chest radiography, a 
tuberculin test (or QuantiFERON–TB Gold assay 
[Cellestis]),22 and symptom questionnaires for 
PML (see the Supplementary Appendix); in addi-
tion, demographic information was obtained. 
Eligible patients were scheduled for a visit im-
mediately before randomization, when sigmoid-
oscopy was performed and baseline Mayo Clinic 
scores and scores on the Inflammatory Bowel 
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Disease Questionnaire (IBDQ; range, 0 to 224, 
with higher scores indicating a better quality of 
life)23 were determined.
Randomization Procedures
For induction therapy, patients were randomly 
assigned, in a 3:2 ratio, to receive intravenous 
vedolizumab (300 mg) or placebo at days 1 and 15 
(cohort 1), with two stratification factors: con-
comitant use or nonuse of glucocorticoids, and 
concomitant use or nonuse of immunosuppres-
sive agents or prior use or nonuse of TNF antago-
nists. The proportion of patients with previous 
exposure to TNF antagonists was limited to 50%.
To fulfill sample-size requirements for the 
maintenance trial, additional patients were en-
rolled in an open-label group (cohort 2), which 
received the same active induction regimen giv-
en in the blinded study. Patients from both co-
horts who had a clinical response to vedoliz u-
mab at week 6 (defined below) were randomly 
assigned, in a 1:1:1 ratio, to receive vedolizumab 
every 8 weeks (with placebo administered every 
other visit to preserve blinding), vedolizumab 
every 4 weeks, or placebo for up to 52 weeks. 
Randomization was stratified according to three 
factors: cohort, concomitant use or nonuse of 
glucocorticoids, and concomitant use or nonuse 
of immunosuppressive agents or prior use or 
nonuse of TNF antagonists. Patients who did not 
have a response to vedolizumab induction thera-
py at week 6 received vedolizumab (300 mg) ev-
ery 4 weeks and were followed through week 52. 
Patients in cohort 1 who received placebo con-
tinued to receive placebo and were followed in a 
similar fashion.
Randomization was performed centrally with 
the use of computer-generated randomization 
schedules. Permitted concomitant medications 
for ulcerative colitis included aminosalicylates, 
glucocorticoids, and immunosuppressive agents. 
Aminosalicylates were continued at stable doses 
throughout the induction and maintenance peri-
ods. Glucocorticoid doses remained unaltered 
until week 6, then were tapered according to a 
defined regimen for patients with a clinical re-
sponse to vedolizumab; immunosuppressants 
were maintained at stable doses throughout the 
induction and maintenance periods, except at 
U.S. sites, where they were discontinued after 
induction (see the Supplementary Appendix).
Follow-up
Patients were seen at weeks 2, 4, and 6 during 
induction therapy and every 4 weeks thereafter 
until week 52. At each visit, a partial Mayo Clinic 
score24 (consisting of the Mayo Clinic score mi-
nus the sigmoidoscopy subscore; range, 0 to 9, 
with higher scores indicating more active dis-
ease) was calculated, adverse events were noted, 
and neurologic-symptom questionnaires were ad-
ministered, with positive responses to objective 
testing prompting further evaluation (see the Sup-
plementary Appendix). Blood samples for serum 
chemical and hematologic testing were obtained 
every 8 weeks, and blood samples for assessment 
of anti-vedolizumab antibodies were obtained 
every 12 weeks. Assessments of fecal calprotectin 
concentrations and IBDQ scores were repeated 
at weeks 6, 30, and 52. Sigmoidoscopy was per-
formed at baseline and weeks 6 and 52. Serum 
vedolizumab concentrations were measured at 
weeks 0, 2, 4, and 6 and approximately every 
8 weeks thereafter. Testing for JC virus antibod-
ies was not performed because a validated assay 
was not commercially available.
Outcomes
The primary outcome for induction therapy was a 
clinical response at week 6, defined as a reduction 
in the Mayo Clinic score of at least 3 points and a 
decrease of at least 30% from the baseline score, 
with a decrease of at least 1 point on the rectal 
bleeding subscale or an absolute rectal bleeding 
score of 0 or 1. Secondary outcomes at week 6 were 
clinical remission, defined as a Mayo Clinic score of 
2 or lower and no subscore higher than 1, and mu-
cosal healing, defined as an endoscopic subscore 
of 0 or 1. The primary outcome for maintenance 
therapy was clinical remission at week 52. Second-
ary measures, in ranked order, were durable clinical 
response (response at both weeks 6 and 52), durable 
clinical remission (remission at both weeks 6 and 
52), mucosal healing at week 52, and glucocorti-
coid-free remission at week 52 in patients receiving 
glucocorticoids at baseline. Health-related quali-
ty of life was evaluated with the use of the IBDQ. 
Adverse events were classified with the use of the 
Medical Dictionary for Regulatory Activities,25 version 15.
Study Oversight
The study was designed and implemented by the 
GEMINI 1 Steering Committee (see the Supple-
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mentary Appendix) in collaboration with Millen-
nium Pharmaceuticals, which held and analyzed 
the data. The study was monitored by means of on-
site visits, with audits conducted at high-enrolling 
centers (see the Supplementary Appendix). Investi-
gators, participating institutions, and the sponsor 
agreed to maintain confidentiality of the data. 
The first draft of the manuscript was written by 
the first author; the academic authors had access 
to the data and vouch for the validity of the data 
and analyses and the fidelity of the study to the 
protocol. All the authors made the decision to 
submit the manuscript for publication. Editorial 
support was funded by Takeda Pharmaceuticals 
International.
Statistical Analysis
Descriptive statistics were used to summarize 
differences in demographic and baseline charac-
teristics among study groups. For the primary 
analysis of induction therapy, proportions of pa-
tients with a clinical response were compared 
with the use of the Cochran–Mantel–Haenszel 
chi-square test, with adjustment for stratification 
factors. Treatment was considered to have failed 
in patients who withdrew prematurely (Table S2 
in the Supplementary Appendix). Rates of clini-
cal remission and endoscopic healing were com-
pared in a similar fashion. To control for multi-
ple comparisons, a closed sequential procedure 
was used for primary and secondary outcomes, 
and a P value of 0.05 or lower was required to 
proceed to the analysis of each subsequent out-
come. A similar procedure was used to analyze 
data from the trial of maintenance therapy. Given 
the comparisons of two vedolizumab doses with 
placebo, a Hochberg procedure26 was used to con-
trol the overall alpha error at 5% for testing of 
both dose regimens for each outcome. Nine sub-
group analyses were prespecified to assess dif-
ferences in remission rates at weeks 6 and 52 
between patients receiving vedolizumab and 
those assigned to placebo.
We analyzed changes from baseline in the 
partial Mayo Clinic score, IBDQ score, and fecal 
calprotectin concentration separately for induc-
tion therapy and maintenance therapy, using 
analysis of covariance with adjustment for strat-
ification variables. Between-group differences in 
glucocorticoid use were assessed by calculating 
median percentage changes from baseline. For 
patients who withdrew prematurely, the last ob-
servation was carried forward. Statistical tests 
were two-sided, with a P value of 0.05 or lower 
considered to indicate statistical significance. 
Analyses were performed according to the inten-
tion-to-treat principle. Descriptive statistics were 
used to compare incidences of adverse events 
between patients who received vedolizumab and 
those who received placebo.
It was anticipated that 35% of patients who 
received placebo and 53% of those who received 
vedolizumab would have a response during 
 induction therapy. Corresponding estimates of 
remission rates at week 52 for the most ef-
fective vedolizumab regimen in the trial of 
maintenance therapy were 30% and 50%. The 
planned enrollment of 375 patients in the trial 
of induction therapy and 372 patients in the 
trial of maintenance therapy provided at least 
90% power to detect differences with an alpha 
error of 5%.5,16
R esult s
Randomization and Baseline Characteristics
In total, 1406 patients were evaluated for eligi-
bility (Fig. S1 in the Supplementary Appendix); 
895 were enrolled and included in the analysis, 
of whom 58 (6.5%) did not meet one or more 
inclusion criteria or met one or more exclusion 
criteria (Table S3 in the Supplementary Appen-
dix). In the trial of induction therapy, 225 pa-
tients were randomly assigned to receive vedo-
lizumab and 149 to receive placebo (cohort 1). 
An additional 521 patients (cohort 2) received 
open-label vedolizumab. Baseline characteristics 
were similar in the placebo group and the vedo-
lizumab group in cohort 1 (Table 1). Previous 
treatment with TNF antagonists had failed in 
approximately 40% of patients.
Patients in either cohort who had a response 
to vedolizumab at week 6 were enrolled in the 
trial of maintenance therapy, with 122, 125, and 
126 patients randomly assigned to receive ve-
dolizumab every 8 weeks, vedolizumab every 
4 weeks, and placebo, respectively. There were no 
clinically important differences in demographic 
or baseline characteristics or in medication his-
tory among the three groups (Table S4 in the 
Supplementary Appendix) or between patients 
who entered from cohort 1 (121 patients) and 
those who entered from cohort 2 (252 patients) 
(data not shown).
The New England Journal of Medicine 
Downloaded from nejm.org on February 12, 2017. For personal use only. No other uses without permission. 
 Copyright © 2013 Massachusetts Medical Society. All rights reserved. 
Vedolizumab for Ulcer ative Colitis
n engl j med 369;8 nejm.org august 22, 2013 703
Table 1. Demographic and Baseline Disease Characteristics and Medication History of Patients in the Induction Trial.*
Characteristic
Placebo
(N = 149) Vedolizumab
Total
(N = 895)
Cohort 1
(N = 225)†
Cohort 2  
(N = 521)
Combined 
(N = 746)
Age — yr 41.2±12.5 40.1±13.1 40.1±13.3 40.1±13.2 40.3±13.1
Male sex — no. (%) 92 (61.7) 132 (58.7) 301 (57.8) 433 (58.0) 525 (58.7)
White race — no. (%)‡ 115 (77.2) 183 (81.3) 436 (83.7) 619 (83.0) 734 (82.0)
Body weight — kg 72.4±17.6 72.4±17.1 74.2±19.3 73.6±18.7 73.4±18.5
Current smoker — no. (%) 11 (7.4) 12 (5.3) 32 (6.1) 44 (5.9) 55 (6.1)
Duration of disease — yr 7.1±7.2 6.1±5.1 7.2±6.6 6.8±6.2 6.9±6.4
Mayo Clinic score§ 8.6±1.7 8.5±1.8 8.6±1.8 8.6±1.8 8.6±1.8
Partial Mayo Clinic score¶ 6.1±1.5 6.0±1.6 6.0±1.6 6.0±1.6 6.0±1.6
IBDQ score‖ 126±34 125±35 121±32 122±33 122±33
Fecal calprotectin — μg/g**
Median 1006 1112 782 868 899
Interquartile range 333–2943 449–2931 331–1594 344–1915 341–2127
Site of disease — no. (%)
Rectum and sigmoid colon only 22 (14.8) 25 (11.1) 69 (13.2) 94 (12.6) 116 (13.0)
Left side of colon 59 (39.6) 92 (40.9) 188 (36.1) 280 (37.5) 339 (37.9)
Proximal to the splenic flexure 18 (12.1) 25 (11.1) 66 (12.7) 91 (12.2) 109 (12.2)
All of the colon 50 (33.6) 83 (36.9) 198 (38.0) 281 (37.7) 331 (37.0)
Concomitant medications for ulcerative  colitis 
— no. (%)
Glucocorticoids only 58 (38.9) 79 (35.1) 195 (37.4) 274 (36.7) 332 (37.1)
Immunosuppressants only†† 18 (12.1) 28 (12.4) 113 (21.7) 141 (18.9) 159 (17.8)
Glucocorticoids and immunosuppressants 26 (17.4) 47 (20.9) 76 (14.6) 123 (16.5) 149 (16.6)
No glucocorticoids or immunosuppressants 47 (31.5) 71 (31.6) 137 (26.3) 208 (27.9) 255 (28.5)
Prednisone-equivalent dose — mg
Median 20.0 20.0 20.0 20.0 20.0
Interquartile range 10.0–30.0 10.0–25.0 10.0–30.0 10.0–25.0 10.0–25.0
Prior anti-TNF therapy — no. (%) 73 (49.0) 95 (42.2) 263 (50.5) 358 (48.0) 431 (48.2)
Prior failure of anti-TNF therapy — no. (%)
≥1 failure 63 (42.3) 82 (36.4) 222 (42.6) 304 (40.8) 367 (41.0)
Inadequate response 29 (46.0) 44 (53.7) 103 (46.4) 147 (48.4) 176 (48.0)
Loss of response‡‡ 26 (41.3) 32 (39.0) 83 (37.4) 115 (37.8) 141 (38.4)
Unacceptable adverse events 8 (12.7) 6 (7.3) 36 (16.2) 42 (13.8) 50 (13.6)
Hemoglobin concentration — g/liter 123.7±19.6 125.2±19.6 124.9±119.5 125.0±19.5 124.8±19.5
White-cell count — ×10−9/liter 8.7±3.3 8.2±3.1 8.6±3.2 8.5±3.2 8.5±3.2
* Plus–minus values are means ±SD. TNF denotes tumor necrosis factor.
† P values for the comparison in cohort 1 between the placebo group and the vedolizumab group are all greater than 0.05.
‡ Race was self-reported.
§ Mayo Clinic scores range from 0 to 12, with higher scores indicating more active disease.19,20
¶ The partial Mayo Clinic score consists of the Mayo Clinic score minus the sigmoidoscopy subscore; range, 0 to 9, with 
higher scores indicating more active disease.
‖ Scores on the Inflammatory Bowel Disease Questionnaire (IBDQ) range from 0 to 224, with higher scores indicating a 
better quality of life.
** Data on fecal calprotectin were available for 857 patients: 139 receiving placebo, 213 receiving vedolizumab in cohort 1, 
505 receiving vedolizumab in cohort 2, and 718 receiving vedolizumab in the combined cohorts.
†† Immunosuppressants included azathioprine and mercaptopurine.
‡‡ Loss of response indicates that the patient had a response initially but subsequently did not have a response.
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Outcomes in the Trial of Induction Therapy
At week 6, a total of 106 of the 225 patients 
 receiving vedolizumab (47.1%) and 38 of the 
149 patients receiving placebo (25.5%) had a 
clinical response (difference with adjustment 
for stratification factors, 21.7 percentage points; 
95% confidence interval [CI], 11.6 to 31.7; 
P<0.001) (Table 2). Efficacy was generally con-
sistent among demographic subgroups and sub-
groups defined by baseline disease characteristics 
(Fig. S2 in the Supplementary Appendix). A total 
of 38 patients receiving vedolizumab (16.9%) and 
8 receiving placebo (5.4%) had clinical remission 
(P = 0.001). Rates of mucosal healing were 40.9% 
(92 of 225 patients) with vedolizumab and 24.8% 
(37 of 149) with placebo (P = 0.001) (Table S5 in 
the Supplementary Appendix). Of the 521 patients 
in cohort 2 who received open-label vedolizumab, 
231 had a clinical response (44.3%), 100 had clin-
ical remission (19.2%), and 191 had mucosal heal-
ing (36.7%).
Outcomes in the Trial of Maintenance 
Therapy
At week 52, patients who were randomly assigned 
to continue receiving vedolizumab were more 
likely to have clinical remission than were those 
randomly assigned to switch to placebo (51 of 
122 patients receiving vedolizumab every 8 weeks 
[41.8%] and 56 of 125 receiving vedo liz umab 
every 4 weeks [44.8%] vs. 20 of 126 re ceiving 
placebo [15.9%]; adjusted difference for vedoliz-
umab every 8 weeks vs. placebo, 26.1 percent-
age points [95% CI, 14.9 to 37.2; P<0.001]; ad-
justed difference for vedolizumab every 4 weeks 
vs. placebo, 29.1 percentage points [95% CI, 
17.9 to 40.4; P<0.001]) (Table 3). Efficacy was 
gen erally consistent among demographic sub-
groups and subgroups defined by baseline dis-
ease char acteristics (Fig. S3 in the Supplemen-
tary Ap pendix).
Rates of durable clinical response, durable 
clinical remission, mucosal healing, and gluco-
corticoid-free remission were higher among pa-
tients assigned to the vedolizumab regimens 
than among those assigned to placebo. No clear 
differences in efficacy were observed between 
the two vedolizumab regimens (Table 3, and 
Table S6 in the Supplementary Appendix). Con-
current treatment with glucocorticoids or im-
munosuppressants or previous treatment with 
TNF antagonists did not substantively affect the 
efficacy of vedolizumab (Fig. S3 in the Supple-
mentary Appendix).
Patients who received vedolizumab had great-
er improvements in the partial Mayo Clinic score, 
IBDQ score, fecal calprotectin concentration, and 
glucocorticoid use than patients assigned to pla-
cebo (Fig. 1). In a post hoc analysis, no clear 
differences in efficacy between the two vedoliz-
umab regimens were apparent (Fig. S3C in the 
Supplementary Appendix).
Safety
No important differences were observed among 
the study groups in the most commonly report-
ed adverse events (Table 4, and Tables S7 and S8 
in the Supplementary Appendix). Serious in-
fections were not more common with vedoliz-
umab than with placebo. No cases of PML oc-
curred. A 66-year-old man who received one 
dose of vedo lizumab died 14 days later of an 
acute  coronary syndrome (see the Supplemen-
tary Appendix). No significant differences in 
hematologic or serum chemical profiles or liver-
function test results were identified among the 
study groups. Unlike other anti-integrin thera-
peutic regimens,27,28 vedolizumab treatment did 
not increase peripheral-blood total lymphocyte 
counts. Clinically important infusion reactions 
were few; three cases (two with detectable anti-
vedolizumab antibodies) resulted in drug dis-
continuation. No cases of anaphylaxis or serum 
sickness were observed.
Table 2. Outcome Measures at Week 6 in the Trial of Induction Therapy.
Outcome
Placebo 
(N = 149)
Vedolizumab  
(N = 225)
Percentage-Point 
Difference 
(95% CI)* P Value
no. (%)
Clinical response† 38 (25.5) 106 (47.1) 21.7 (11.6–31.7) <0.001
Clinical remission‡ 8 (5.4) 38 (16.9) 11.5 (4.7–18.3) 0.001
Mucosal healing§ 37 (24.8) 92 (40.9) 16.1 (6.4–25.9) 0.001
* Percentage-point differences were adjusted for two stratification factors: con-
comitant use or nonuse of glucocorticoids, and concomitant use or nonuse of 
immunosuppressive agents or prior use or nonuse of TNF antagonists.
† A clinical response was defined as a reduction in the Mayo Clinic score of at 
least 3 points and a decrease of at least 30% from the baseline score, with a 
decrease of at least 1 point on the rectal bleeding subscale or an absolute 
 rectal bleeding score of 0 or 1.
‡ Clinical remission was defined as a Mayo Clinic score of 2 or lower and no 
subscore higher than 1.
§ Mucosal healing was defined as a Mayo Clinic scale endoscopic subscore of 
0 or 1.
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Pharmacokinetics and Immunogenicity
The mean (±SD) trough vedolizumab concentra-
tion was 27.9±15.5 μg per milliliter (in 654 pa-
tients) at week 6. At steady state, mean vedo-
lizumab concentrations were 11.2±7.2 μg per 
milliliter with vedolizumab every 8 weeks (in 
77 patients) and 38.3±24.4 μg per milliliter with 
vedolizumab every 4 weeks (in 220 patients); 
both dosing schedules resulted in more than 
95% saturation of α4β7 of CD4+CD45RO+ T cells 
in the peripheral circulation (data not shown). 
Correlations between drug level and response 
during induction therapy and maintenance ther-
apy are shown in Figures S4 and S5, respectively, 
in the Supplementary Appendix. Of 620 vedo-
lizumab-treated patients with available blood 
samples, 23 (3.7%) had samples that were posi-
tive for anti-vedolizumab antibodies at any time, 
and 6 (1.0%) had samples that were persistently 
positive (i.e., ≥2 consecutive positive samples) 
through week 52. Concomitant immunosuppres-
sive therapy was associated with decreased im-
munogenicity (data not shown).
Discussion
In these trials, vedolizumab was effective for in-
ducing and maintaining a response and remis-
sion in patients with ulcerative colitis. All pre-
specified primary and secondary outcomes in the 
trials of induction and maintenance therapy were 
superior in vedolizumab-treated patients versus 
those who received placebo. Longitudinal assess-
ments of partial Mayo Clinic scores, IBDQ scores, 
fecal calprotectin concentrations, and use or 
dose of glucocorticoids provided further evidence 
of a treatment benefit. Disease had been refrac-
tory to other treatments in many patients; treat-
ment with TNF antagonists, agents usually re-
served for more severe disease,29 had previously 
failed in approximately 40% of patients, many of 
whom had not had a response (Table 1). Of par-
ticular relevance was the benefit of vedolizumab 
therapy with respect to glucocorticoid-free re-
mission. At week 52, this outcome was observed 
in 31.4% of the patients who received vedoliz-
umab every 8 weeks and in 45.2% of those who 
received vedolizumab every 4 weeks, as compared 
with 13.9% of patients who received placebo. 
This benefit was not appreciably affected by sta-
tus with respect to concurrent or prior treat-
ments for ulcerative colitis.
Although the trial of maintenance therapy 
was not large enough or of sufficient duration to 
estimate the risk of uncommon adverse events, 
rates of serious, opportunistic, or enteric in-
Table 3. Outcome Measures in the Trial of Maintenance Therapy.
Outcome
Placebo
(N = 126)
Vedolizumab Every  
8 Wk (N = 122)
Vedolizumab Every 
4 Wk (N = 125) Between-Group Difference*
Every 8 Wk 
vs. Placebo P Value
Every 4 Wk 
vs. Placebo P Value
number/total number (percent)
percentage points 
(95% CI)
percentage points 
(95% CI)
Clinical remission at wk 52 20/126
(15.9)
51/122
(41.8)
56/125
(44.8)
26.1
(14.9–37.2)
<0.001 29.1
(17.9–40.4)
<0.001
Durable clinical  response† 30/126
(23.8)
69/122
(56.6)
65/125
(52.0)
32.8
(20.8–44.7)
<0.001 28.5
(16.7–40.3)
<0.001
Durable clinical  remission‡ 11/126
(8.7)
25/122
(20.5)
30/125
(24.0)
11.8
(3.1–20.5)
0.008 15.3
(6.2–24.4)
0.001
Mucosal healing at wk 52 25/126
(19.8)
63/122
(51.6)
70/125
(56.0)
32.0
(20.3–43.8)
<0.001 36.3
(24.4–48.3)
<0.001
Glucocorticoid-free remission 
at wk 52§
10/72
(13.9)
22/70
(31.4)
33/73
(45.2)
17.6
(3.9–31.3)
0.01 31.4
(16.6–46.2)
<0.001
* Between-group differences in percentage points were adjusted for three stratification factors: cohort, concomitant use or nonuse of gluco-
corticoids, and concomitant use or nonuse of immunosuppressive agents or prior use or nonuse of TNF antagonists.
† A durable clinical response was defined as a response at both weeks 6 and 52.
‡ Durable clinical remission was defined as remission at both weeks 6 and 52.
§ This outcome was assessed in patients receiving oral glucocorticoids at baseline.
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fections with vedolizumab did not differ signif-
icantly from the rates with placebo, and no dose–
response relationship was observed. Infections 
were more common in a companion trial, also 
reported in this issue of the Journal, of vedoliz-
umab in patients with Crohn’s disease.30 Longer-
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term epidemiologic studies and clinical experi-
ence are required to more fully assess the risk of 
adverse events associated with vedolizumab.
As of February 2013, no cases of PML had 
been reported in approximately 3000 patients 
exposed to vedolizumab for a median of 18.8 
months (mean, 20.9 months; range, 4 to 67). 
Approximately 2400 of these patients (80%) had 
previously received immunosuppressive agents, 
and 900 were exposed to vedolizumab for more 
than 24 months. Testing for JC virus antibodies 
was not performed in this study, owing to the 
lack of a validated commercially available assay. 
The reported prevalence of detectable antibodies 
to JC virus, which are indicative of prior expo-
sure, has ranged from 50 to 80% in diverse 
populations, including patients with Crohn’s 
disease.31-38 In comparison, the incidence of 
PML among patients receiving natalizumab ther-
apy for multiple sclerosis exceeds 1 case in 500 
patients overall (range, approximately 1 in 3000 
[0.3 in 1000] among patients with ≤24 months’ 
exposure and no prior use of immunosuppres-
sive agents to approximately 1 in 150 [6.7 in 
1000] among those with >24 months’ exposure 
and prior use of immunosuppressive agents).39
The development of neutralizing antibodies 
can increase drug clearance, reduce treatment 
efficacy, and affect safety. In contrast to our 
experience with MLN02, the precursor of vedo-
liz umab, the rate of sensitization observed with 
vedolizumab was relatively low, despite substan-
tially longer exposure. This finding may be at-
tributable to an improved manufacturing pro-
cess and the potentially tolerizing effect of the 
higher vedolizumab doses administered in this 
study.
Our study had important limitations. First, it 
was not designed to identify the time of the 
maximal effect of vedolizumab as induction 
therapy. Greater efficacy may be obtained by 
extending induction treatment beyond 6 weeks. 
Second, we did not identify a minimally effective 
dose regimen, because both treatment schedules 
fully saturated the α4β7 integrin on peripheral-
blood lymphocytes and no substantial efficacy 
Table 4. Adverse Events Affecting at Least 5% of Patients Receiving 
Vedolizumab in the Safety Population.*
Event
Placebo 
(N = 275)
Vedolizumab 
(N = 620)
no. of patients (%)
Headache 28 (10.2) 80 (12.9)
Ulcerative colitis 58 (21.1) 97 (15.6)
Nasopharyngitis 26 (9.5) 80 (12.9)
Upper respiratory tract infection 21 (7.6) 52 (8.4)
Arthralgia 25 (9.1) 56 (9.0)
Nausea 19 (6.9) 38 (6.1)
Abdominal pain 10 (3.6) 35 (5.6)
Anemia 16 (5.8) 35 (5.6)
Fatigue 10 (3.6) 33 (5.3)
Cough 13 (4.7) 36 (5.8)
Any serious adverse event 37 (13.5) 77 (12.4)
Any serious infection† 8 (2.9) 12 (1.9)
Any cancer 3 (1.1)‡ 1 (0.2)§
* Adverse events were classified according to the Medical Dictionary for Regulatory 
Activities System Organ Class categorization and preferred terms. Patients with 
more than one event in a category were counted only once if the start and stop 
dates of the multiple events overlapped or if the start and stop dates were the 
same; if the start and stop dates of the multiple events did not overlap, they were 
counted as separate events. The safety population was defined as all patients who 
received at least one dose of the study drug. The vedolizumab group includes 
patients who received maintenance therapy with vedolizumab (patients who 
had a response to vedolizumab as induction therapy and who were assigned 
to vedolizumab every 4 weeks or every 8 weeks during the trial of maintenance 
therapy and patients who did not have a response to vedolizumab as induction 
therapy). The placebo group includes patients who did not receive maintenance 
therapy with vedolizumab (patients assigned to placebo during the trial of in-
duction therapy and patients who had a response to vedolizumab during that 
trial and who were assigned to placebo in the trial of maintenance therapy). See 
Tables S7 and S8 in the Supplementary Appendix for a further breakdown of 
adverse events in the study groups.
† A serious infection was defined as a serious adverse event of infection according 
to the Medical Dictionary for Regulatory Activities (version 15) criteria.
‡ Colon cancer, transitional-cell carcinoma, and squamous-cell carcinoma of the 
skin occurred in one patient each in the placebo group.
§ Colon cancer occurred in one patient in the vedolizumab group.
Figure 1 (facing page). Exploratory Outcomes in the 
Trials of Vedolizumab as Induction and Maintenance 
Therapy.
Panel A shows partial Mayo Clinic scores, which range 
from 0 to 9, with higher scores indicating more active 
disease. Panel B shows scores on the Inflammatory 
Bowel Disease Questionnaire (IBDQ), which range 
from 0 to 224, with higher scores indicating a better 
quality of life. I bars in Panels A and B indicate stan-
dard errors. Panel C shows median fecal calprotectin 
concentrations. I bars indicate the interquartile range. 
Panel D shows the median change from week 6 in 
prednisone-equivalent doses. Patients receiving place-
bo during the trial of maintenance therapy received 
two doses of vedolizumab during the trial of induction 
therapy. For patients who withdrew early, the last ob-
servation was carried forward (Panels A, B [graph at 
right], C [graph at right], and D).
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differences were noted between regimens. These 
observations suggest that vedolizumab given ev-
ery 8 weeks may be an acceptable starting regi-
men, with the possibility of dose intensification 
if the response is inadequate.
In conclusion, vedolizumab is effective as 
both induction and maintenance therapies for 
patients with moderately to severely active ul-
cerative colitis.
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